PECAM1 and neoplasm: In the present study, we have demonstrated the efficacy of Nintedanib in decreasing angiogenesis in xenograft tumors, since microvessel density measured by CD31 immunostaining in the tumors was significantly reduced in both experiments, concluding that not only was the drug highly effective when administered in early stages of tumor development, but also when angiogenesis was already established.